ALPHARETTA, Ga., May 23, 2016 /PRNewswire/ — The President and CEO of Ennaid Therapeutics, Darnisha Harrison, will be speaking at the 2016 ISNTD d3 conference. The conference will take place on May 25th and 26th in London, United Kingdom and will address the drug discovery, development and diagnostics equation over two days. This is truly an honor for Ennaid Therapeutics as the company is diligently developing antiviral drugs to treat Zika virus, dengue virus and many other emerging mosquito-borne diseases.
The ISNTD is an independent not-for-profit organization providing a multidisciplinary global platform to alleviate the burden of NTDs on the world’s poorest and most vulnerable, with the ultimate goal of reaching sustainable healthcare provision & poverty reduction in the developing world. The purpose of this conference (ISNTD d3) is to address the past shortfalls in R&D productivity and drive the development of future paths towards successful gains in the control, treatment or evaluation of NTDs. ISNTD d3 will bring together experts from within drug discovery and clinical trials to drive the debate and foster new partnerships & alliances leading to tangible outcomes in terms of new therapies to combat these diseases.
“We are honored to be selected to participate in this relevant conference,” says Darnisha Harrison, Ennaid Therapeutics’ President & CEO, “as we, too, have a goal to bring sustainable healthcare to the globally diverse regions of the world by developing therapeutics that bring hope to endemic countries being plagued by Zika, Dengue and Chikungunya viruses.”